本文選題：加味二陳平胃散 + 支擴(kuò)繼發(fā)感染痰濁阻肺夾熱證��； 參考：《黑龍江中醫(yī)藥大學(xué)》2016年碩士論文

【摘要】：目的：觀察加味二陳平胃散治療支氣管擴(kuò)張繼發(fā)感染(痰濁阻肺夾熱證)患者的臨床癥狀、體征的改變及對(duì)血清中CRP的影響。方法：選擇符合支氣管擴(kuò)張繼發(fā)感染(痰濁阻肺夾熱證)患者72例,隨機(jī)分為治療組36例和對(duì)照組36例。實(shí)際完成人數(shù)治療組35例,1例剔除(因違背試驗(yàn)方案),對(duì)照組34例,2例脫落(1例失訪,1例病情加重)。對(duì)照組給予拜復(fù)樂(lè)及切諾口服治療,治療組在對(duì)照組的基礎(chǔ)上給予加味二陳平胃散中藥湯劑。觀察患者治療前后的臨床癥狀、體征,ELISA法檢測(cè)患者治療前后血清中CRP含量的改變。結(jié)果：1.加味二陳平胃散治療支氣管擴(kuò)張繼發(fā)感染(痰濁阻肺夾熱證)臨床療效顯著,其總有效率分別為：治療組94.29%,對(duì)照組76.47%。兩組比較差異顯著,有統(tǒng)計(jì)學(xué)意義(P0.05)。2.加味二陳平胃散可顯著改善支氣管擴(kuò)張繼發(fā)感染(痰濁阻肺夾熱證)患者的臨床癥狀,特別在改善胸悶、脘痞、納呆等方面,治療組明顯優(yōu)于對(duì)照組(P0.05)。3.兩組患者治療前后肺部Up音均有改善,但兩組比較無(wú)顯著差異,無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。4.兩組患者治療前后WBC及NEUT％的值均明顯下降,組間比較無(wú)顯著差異(P0.05)。5.兩組患者治療前后血清中CRP含量明顯下降,且治療組與對(duì)照組比較有顯著差異(P0.05)。6.兩組患者治療前后安全性指標(biāo)無(wú)明顯異常。結(jié)論：1.加味二陳平胃散對(duì)支擴(kuò)繼發(fā)感染(痰濁阻肺夾熱證)患者的臨床療效顯著,特別對(duì)咳嗽、咳痰、胸悶、脘痞、納呆癥狀有明顯改善。2.加味二陳平胃散能有效降低支擴(kuò)繼發(fā)感染(痰濁阻肺夾熱證)患者血清中CRP的含量。
[Abstract]:Objective: to observe the changes of clinical symptoms and signs in patients with bronchiectasis secondary infection (phlegm turbid obstruction of lung heat entrapment) treated with Jiawei er Chen Ping Wei San and its effect on serum CRP. Methods: 72 cases of bronchiectasis secondary infection (phlegm turbid obstruction of lung heat) were randomly divided into treatment group (36 cases) and control group (36 cases). In the treatment group, 35 cases were removed from the treatment group and 1 case was removed. (34 cases in the control group were removed and 1 case lost one case, 1 case became worse. The control group was treated with Baifule and Chenuo orally, the treatment group was treated with Jiawei er Chen Ping Wei San decoction on the basis of the control group. To observe the clinical symptoms and signs of the patients before and after treatment and to detect the changes of serum CRP levels before and after treatment by enzyme-linked immunosorbent assay (Elisa). The result is 1: 1. The clinical efficacy of Jiawei er Chen Ping Weisan in treating bronchiectasis secondary infection (phlegm turbid obstruction of lung heat entrapment syndrome) was remarkable. The total effective rate was 94.29 in the treatment group and 76.477in the control group. The difference between the two groups was significant (P 0.05. 2). Jiawei er Chen Ping Weisan could significantly improve the clinical symptoms of patients with bronchiectasis secondary infection (phlegm turbid obstruction of lung heat entrapment syndrome), especially in the improvement of chest tightness, epigastric distension and insufflation, the treatment group was significantly better than the control group (P0.05G. 3). There was no significant difference between the two groups before and after treatment, but there was no significant difference between the two groups. Before and after treatment, the values of WBC and NEUT% were significantly decreased in both groups, and there was no significant difference between the two groups (P 0.05. 5). The level of serum CRP in the two groups decreased significantly before and after treatment, and there was a significant difference between the treatment group and the control group (P 0.05. 6). Before and after treatment, the safety indexes of the two groups were not significantly abnormal. Conclusion 1. The clinical effect of Jiawei er Chen Ping Weisan on patients with secondary infection (phlegm turbid obstruction of lung and heat entrapment) was significant, especially for cough, expectoration, chest tightness, epigastric distension and anorexia. Jiawei er Chen Ping Weisan powder can effectively reduce the content of CRP in serum of patients with secondary infection (phlegm turbid obstruction of lung heat).
【學(xué)位授予單位】：黑龍江中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R259

【相似文獻(xiàn)】

相關(guān)期刊論文 前4條

1 曹鴻壽;;從“痰”辨證驗(yàn)案四則[J];天津中醫(yī);1992年06期

2 張偉;劉新橋;;中藥治療慢性支氣管炎急性發(fā)作(痰濕郁肺證)28例[J];中國(guó)中醫(yī)急癥;2011年04期

3 牛忻群;;二陳平胃治便秘[J];湖北中醫(yī)雜志;1990年02期

4 ;[J];;年期

相關(guān)碩士學(xué)位論文 前1條

1 胡慧珍;加味二陳平胃散治療支擴(kuò)繼發(fā)感染（痰濁阻肺夾熱證）的臨床觀察及對(duì)CRP的影響[D];黑龍江中醫(yī)藥大學(xué);2016年

，

本文編號(hào)：1978172